Analysts Set Masimo Co. (NASDAQ:MASI) Target Price at $194.80

Shares of Masimo Co. (NASDAQ:MASI - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $194.80.

MASI has been the subject of several research analyst reports. Stifel Nicolaus reissued a "buy" rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler upped their price objective on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company upped their price objective on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th.

Insiders Place Their Bets

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Masimo

A number of large investors have recently made changes to their positions in MASI. Jones Financial Companies Lllp bought a new stake in shares of Masimo in the 4th quarter worth approximately $27,000. UMB Bank n.a. grew its position in shares of Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new stake in shares of Masimo in the 4th quarter worth approximately $33,000. Blue Trust Inc. grew its position in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Price Performance

MASI stock traded down $3.05 during midday trading on Monday, reaching $169.70. The company had a trading volume of 234,498 shares, compared to its average volume of 621,493. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 116.69 and a beta of 1.04. The stock has a 50 day moving average price of $174.99 and a 200-day moving average price of $158.78. Masimo has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities research analysts expect that Masimo will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.